Checks how guselkumab works for psoriatic arthritis using ultrasound scans
Studies guselkumab in adults with psoriatic arthritis, a joint disease linked to psoriasis.
Plain-language title generated from the registry record
Registry title: A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
Key facts
- Where
- Bari, Brescia, Iesi, Milan, Naples, Palermo, Pavia, Perugia, Pisa, Potenza, Reggio Emilia, Roma, Siena, Torino, Varese, and Verona, ItalySee the 21 sites
Where in Italy
- Policlinico di BariBari, ItalyTaking people
- ASST Spedali Civili BresciaBrescia, ItalyTaking people
- Hospital Carlo UrbaniIesi, ItalyTaking people
- ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyTaking people
- IRCCS Ospedale Galeazzi Sant'AmbrogioMilan, ItalyTaking people
- Istituto Ortopedico Gaetano PiniMilan, ItalyTaking people
- San Raffaele HospitalMilan, ItalyTaking people
- Azienda Ospedaliera Universitaria Federico IINaples, ItalyTaking people
- Seconda Univesità degli Studi di Napoli, AOUNaples, ItalyTaking people
- Azienda Ospedaliero Universitaria Policlinico Paolo GiacconePalermo, ItalyNo longer taking part
- Fondazione IRCCS Policlinico San MatteoPavia, ItalyTaking people
- Università degli Studi di PerugiaPerugia, ItalyTaking people
- Ospedale Santa Chiara AO Universitaria PisanaPisa, ItalyTaking people
- Ospedale San Carlo Di Potenza - Azienda Ospedaliera RegionalePotenza, ItalyTaking people
- Arcispedale Santa Maria Nuova - IRCCSReggio Emilia, ItalyTaking people
- Fondazione Policlinico Universitario A. Gemelli IRCCSRoma, ItalyTaking people
- Policlinico Di Tor VergataRoma, ItalyTaking people
- A O Universitaria Senese Ospedale Santa Maria alle ScotteSiena, ItalyTaking people
- AO Ordine MaurizianoTorino, ItalyTaking people
- ASST dei Sette Laghi, Ospedale di Circolo e Fonazione MacchiVarese, ItalyTaking people
- Azienda Ospedaliera Universitaria Integrata VeronaVerona, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT07220824
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to assess how well guselkumab works in improving symptoms of psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches) using muscoloskeletal ultrasound (MSUS) in a real-world setting.Read full original descriptionShow less
GUselkumab for the Treatment of PsA: Effectiveness Results by Ultrasound
The purpose of this study is to assess how well guselkumab works in improving symptoms of psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches) using muscoloskeletal ultrasound (MSUS) in a real-world setting.
Inclusion: Diagnosis of PsA as per CASPAR classification criteria for at least six months with active PsA defined as a tender joint count (TJC) greater than or equal to (>=) 3/68 and a swollen joint count (SJC) >= 3/66 at baseline, or C-reactive protein (CRP) >=0.3 milligrams per deciliter (mg/dL) if TJC and/or SJC are less than (<) 3; a) Total synovitis power doppler ultrasound (PDUS) score >=2 and inflammation related to power doppler (PD) signal >=2 for at least 1 affected joint of 48 joints at the baseline visit (before first Guselkumab administration), or b) Total synovitis PDUS score >=2 and inflammation related to PD signal >=1 for at least 2 affected joints of 48 joints at the baseline visit (before first Guselkumab administration); Start guselkumab for the indication of PsA as part of standard clinical practice at the time of enrollment into the observational study or within a maximum of two weeks after the initial baseline visit; Participants must be biologic-naïve or previously exposed to only one biologic Disease-Modifying Antirheumatic Drugs (bDMARD) and/or apremilast/deucravacitinib; At least one clinically involved enthesitis site, defined by SPARCC index >= 1, and one imaging-detected enthesitis site at baseline.
Exclusion: Previous exposure to Guselkumab or to more than one bDMARD for any indications; Prior treatment with Janus kinase (JAK) inhibitors; Contraindications to Guselkumab as per the summary of product characteristics (SmPC); Current enrollment in other investigational study or participation in other investigational study completed from less than 30 days; Current enrollment in an observational study with Guselkumab sponsored or managed by sponsor.